Clinical Trial: Medication Treatment for Depression in Nursing Home Residents

This study is currently recruiting patients.

Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)


The purpose of this study is to examine the effects of continuing antidepressant medication in nursing home residents who no longer have depressive symptoms. The usefulness of continuing maintenance treatment for depression will be determined.

Condition Treatment or Intervention Phase
 Drug: Antidepressants
Phase IV

MedlinePlus related topics:  Depression

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: Drug Treatment of Depression in the Nursing Home Aged

Further Study Details: 

Expected Total Enrollment:  240

Study start: November 2003;  Expected completion: August 2008

There are approximately 1.6 million nursing home residents in the United States. More than one third of these residents are taking antidepressant medications (ADs). Although ADs are effective, evidence suggests that they can lead to significant adverse events, including an increased risk of bone fractures and impairments of the nervous system which increase the risk of dangerous falls. Many depressed nursing home residents suffer from an initial episode of late life depression and do not meet guideline-based recommendations for maintenance treatment. This study will examine the benefits and risks of long-term AD treatment in depressed nursing home residents whose depression has been in remission.

Participants will be randomly assigned to either continue or discontinue AD treatment. Participants will be monitored for recurrence of depression and related symptoms for 1 year. Self reports and depression scales will be used to assess participants.


Ages Eligible for Study:  65 Years and above,  Genders Eligible for Study:  Both


Inclusion Criteria:

  • Current use of antidepressant medication
  • Have been in remission from first episode of depression for 6 months or longer
  • Of sound mind

Exclusion Criteria:

  • Bedridden
  • Severe cognitive impairment

Location and Contact Information

Suzan DiFilippo      215-349-8228
Ira R. Katz, MD, PhD      215-349-8226

      University of Pennsylvania, Philadelphia,  Pennsylvania,  19104,  United States; Recruiting
Ira R. Katz, MD, PhD,  Principal Investigator

More Information

Study ID Numbers:  MH51247-11A1
Record last reviewed:  March 2005
Last Updated:  March 24, 2005
Record first received:  January 28, 2004 Identifier:  NCT00076622
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005